During his experience as an M.D. and professor in the healthcare and academic domains, James Goydos has performed several clinical trials which have helped shape understanding and treatment of cancer, soft tissue tumors, and melanoma. He has amassed over 80 authored or co-authored, abstracts, patents and publications to his name.
Goydos' work has directly translated into clinical trials for patients with melanoma. His collaborative inventions and research have revolutionized early skin cancer detection, treatment, and prevention both in his home state of New Jersey and across the international medical community.
A method for inhibiting melanoma cell growth in a patient by administering to the patient a therapeutically effective amount of a glutamate release inhibitor, a GRM1 antagonist, or a combination thereof
The present invention provides methods of treating cancer using 2-amino-6-trifluoromethoxybenzothiazole (riluzole). In one aspect, the present invention provides methods of reducing cancer cell growth. In another aspect, the present invention provides a method of inducing apoptosis in a cancer cell. In another aspect, the present invention provides a method of reducing the growth of a glutamate-releasing tumor.
The present invention is directed to a novel method for detecting a mutation in a target nucleic acid sequence. Such methods may be used to detect a mutation in a target nucleic acid sequence derived from a biological sample. Exemplary biological samples include, but are not limited to, samples derived from patients such as bodily fluids, tissues or cells. The methods of the invention are useful for detecting a mutation in a target nucleic acid sequence in such patient samples and thus, are of utility for diagnosing a disease in a patient and/or predicting a predisposition of a patient for a disease.
Disclosed is a method of treating a tumor in a patient, comprising (a) administering riluzole in an amount effective to sensitize the tumor cells to ionizing radiation, and (b) irradiating the tumor cells with ionizing radiation in a dose effective to reduce tumor cell growth. The method can further comprise administering an effective amount of one or more additional therapeutic agents.
This site links to third-party sites which are not maintained by James Goydos, M.D. We are not responsible for the content or privacy practices of any third-parties. We make no representation regarding the accuracy of content in such third-party sites. The inclusion of a third-party link does not imply endorsement.